Long-Term Dosing Proves Isis’ Mipomersen Safe
This article was originally published in The Pink Sheet Daily
Option to self-administer the Phase III lipid-lowering drug could boost sales.
You may also be interested in...
Firm talent-spots PCSK9 compound to the tune of $2 million.
In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.
Genzyme calls mipomersen, currently in Phase III, a blockbuster after gaining rights in potential $1.9 billion deal.